12,348 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by IMA Wealth Inc.

IMA Wealth Inc. purchased a new position in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 12,348 shares of the company’s stock, valued at approximately $2,437,000.

Other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP raised its stake in Zoetis by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after acquiring an additional 297,044 shares in the last quarter. Northern Trust Corp raised its stake in Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after acquiring an additional 196,771 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Zoetis by 3.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,998,989 shares of the company’s stock valued at $695,744,000 after acquiring an additional 150,918 shares in the last quarter. Royal Bank of Canada raised its stake in Zoetis by 3.1% during the 3rd quarter. Royal Bank of Canada now owns 3,026,518 shares of the company’s stock valued at $526,553,000 after acquiring an additional 91,713 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in Zoetis by 1.4% during the 3rd quarter. Blair William & Co. IL now owns 2,428,509 shares of the company’s stock valued at $422,512,000 after acquiring an additional 32,918 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares in the company, valued at $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 2,209 shares of company stock valued at $371,293. Insiders own 0.12% of the company’s stock.

Zoetis Stock Up 3.3 %

ZTS traded up $5.06 during trading on Friday, reaching $158.42. 5,236,463 shares of the stock traded hands, compared to its average volume of 4,019,007. The stock has a market cap of $72.45 billion, a price-to-earnings ratio of 31.25, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock’s 50-day simple moving average is $171.79 and its two-hundred day simple moving average is $179.29.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same period in the prior year, the firm earned $1.15 EPS. Zoetis’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, equities research analysts expect that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. Zoetis’s dividend payout ratio is presently 34.12%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Stifel Nicolaus lowered their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Barclays lowered their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $218.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.